Actively Recruiting
AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2024-12-04
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A prospective, single-arm, exploratory phase II clinical study evaluating the efficacy of Gemcitabine and Nab-palitaxe combined with Cadonilimab sequential short-course radiotherapy in the treatment of patients with locally advanced pancreatic ductal adenocarcinoma.
CONDITIONS
Official Title
AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide written informed consent before any study procedures
- Aged between 18 and 75 years
- Diagnosed with pancreatic cancer confirmed by tissue examination
- Locally advanced pancreatic ductal adenocarcinoma without prior anti-tumor treatment
- Have at least one measurable tumor lesion on imaging
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected survival of more than 3 months
- Adequate organ function meeting specific blood and liver test criteria
- Negative pregnancy test for women of childbearing potential before treatment start
- Use effective contraception during treatment and for 120 days after last study drug dose
You will not qualify if you...
- Having another malignant disease diagnosed within 5 years except certain skin cancers
- Participating in another interventional clinical trial or using study drugs/devices within 4 weeks
- Previous treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or similar immune therapies
- Systemic use of certain Chinese patent medicines or immunomodulatory drugs within 2 weeks before treatment
- Active autoimmune disease needing systemic therapy within 2 years
- Use of systemic glucocorticoids or immunosuppressants within 7 days before treatment start
- History of organ or stem cell transplantation (except corneal)
- Allergy to carfilzomib, gemcitabine, or albumin-bound paclitaxel ingredients
- Not fully recovered from prior treatment toxicities above Grade 1 except fatigue or hair loss
- Known HIV infection
- Uncontrolled active hepatitis B or active hepatitis C infection
- Recent live vaccine use within 30 days before treatment
- Pregnant or breastfeeding women
- Severe or uncontrolled systemic diseases including heart problems, unstable angina, recent arterial thrombosis, poorly controlled blood pressure, lung diseases, infections, liver disease, poorly controlled diabetes, significant proteinuria, or mental disorders
- Any other condition that might interfere with study participation or results as determined by the investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300052
Actively Recruiting
Research Team
R
Rui Liu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here